tiprankstipranks
Trending News
More News >
Perimeter Medical Imaging AI (TSE:PINK)
:PINK

Perimeter Medical Imaging AI (PINK) AI Stock Analysis

Compare
19 Followers

Top Page

TS

Perimeter Medical Imaging AI

(PINK)

Rating:50Neutral
Price Target:
Perimeter Medical Imaging AI is positioned in a growth phase with strong revenue increases and promising clinical advancements towards FDA approval. However, persistent net losses, cash flow constraints, and bearish technical indicators pose significant challenges. The valuation remains unattractive, but recent strategic corporate events offer potential for future expansion.

Perimeter Medical Imaging AI (PINK) vs. iShares MSCI Canada ETF (EWC)

Perimeter Medical Imaging AI Business Overview & Revenue Model

Company DescriptionPerimeter Medical Imaging AI, Inc., a medical technology company, develops and commercializes advanced imaging tools that allow surgeons, radiologists, and pathologists to visualize microscopic tissue structures during a clinical procedure. The company offers an optical coherence tomography (OCT) imaging system provides clinicians with cross-sectional of tissues down to 2 mm dept. This OCT imaging system consists of S-series OCT, B-series OCT, and OCT imaging console. It also offers ImgAssist, an artificial intelligence technology that enhances the efficiency of image review and be an additional powerful tool when combined with Perimeter OCT to aid physicians with real-time margin visualization and assessment to improve surgical outcomes for patients and reducing the likelihood of needing additional surgeries. In addition, the company offers proprietary image library and consumable specimen containers to hospitals and cancer surgery centers. Perimeter Medical Imaging AI, Inc. was founded in 2013 and is headquartered in Toronto, Canada.
How the Company Makes MoneyPerimeter Medical Imaging AI makes money primarily through the sale and leasing of its imaging devices to hospitals and surgical centers. The company also generates revenue from service agreements, maintenance contracts, and by offering training and support for its technology. Additionally, Perimeter may engage in partnerships with healthcare providers and research institutions to expand the application of its technology and drive adoption, which can further contribute to revenue through collaborative agreements and research grants. Key revenue streams include direct sales of imaging devices, recurring revenue from ongoing service and maintenance, and strategic partnerships that enhance their market presence.

Perimeter Medical Imaging AI Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: -33.33%|
Next Earnings Date:Sep 02, 2025
Earnings Call Sentiment Positive
The earnings call demonstrates strong positive momentum with significant revenue growth, successful trial results, and strategic milestones achieved. Despite an increased net loss and the need for additional capital, the overall sentiment is positive due to the promising progress and future potential of the company's products.
Q1-2025 Updates
Positive Updates
Significant Revenue Increase
The company recorded a revenue of $550,000 for the first quarter of 2025, marking a 460% increase over Q1 2024.
Commercial Milestones Achieved
Perimeter achieved multiple commercial milestones including the first capital unit sale, record patient cases, and the highest number of consumables shipped.
Successful Pivotal Trial for B-Series
The pivotal trial for the B-Series OCT system met its primary endpoint with a statistically significant reduction in patients with residual cancer, achieving a margin accuracy of 88.1%.
FDA Pre-Market Approval Application
The company filed a pre-market approval application for the B-Series OCT with the FDA in March 2025 and engaged in positive dialogue with the agency.
Presentation at ASBrS Conference
Dr. Alastair Thompson presented detailed study results of the B-Series pivotal trial at the ASBrS conference, drawing significant attention from researchers and clinicians.
Negative Updates
Increased Net Loss
The company reported a net loss of $4.3 million for Q1 2025, compared to a $2.1 million loss in the same period of 2024.
Need for Additional Capital
Perimeter indicated the need for additional capital to continue executing its growth strategy, with cash and cash equivalents at $2.4 million as of March 31, 2025.
Company Guidance
During the Q1 2025 conference call for Perimeter Medical, the company provided several key financial metrics and strategic updates. The company reported revenue of $550,000 for the quarter ending March 31, 2025, which marked a 460% increase from Q1 2024. Operating expenses remained steady at $4.6 million, while the net loss increased to $4.3 million compared to $2.1 million in the same period in 2024. Cash and cash equivalents stood at approximately $2.4 million, excluding a grant receivable of $931,000. Significant achievements included the first-ever capital unit sale and surpassing $1 million in billings for 2025. The company also expanded into three new states: New Mexico, Tennessee, and Arizona. Strategically, Perimeter is focusing on the commercialization of its FDA-cleared S-Series OCT system and pursuing FDA approval for its B-Series OCT system with ImgAssist AI 2.0, which recently showed promising results in a pivotal clinical trial. The company is also working on broadening its user base and preparing for a potential full commercial launch contingent upon FDA approval of the B-Series.

Perimeter Medical Imaging AI Financial Statement Overview

Summary
Perimeter Medical Imaging AI is in a growth phase with increasing revenues but faces significant financial challenges, notably in profitability and cash flow management. The company has a strong equity base with minimal debt, providing some financial stability, but needs to address its ability to generate positive cash flow and achieve profitability to ensure long-term sustainability.
Income Statement
40
Negative
Perimeter Medical Imaging AI has shown a significant increase in revenue over the years, although it remains relatively low. The gross profit margin for the TTM is healthy at 59.45%, indicating efficient cost management relative to revenue. However, the company continues to sustain substantial losses, reflected in a negative net profit margin of -2477.50% and negative EBIT and EBITDA margins, indicating challenges in achieving operational profitability.
Balance Sheet
55
Neutral
The company maintains a low debt-to-equity ratio of 0.01, suggesting minimal leverage and low financial risk. However, the equity ratio is 81.74%, indicating strong reliance on equity financing. The negative net income affects the return on equity, which is also negative, suggesting inefficient use of shareholder funds to generate returns.
Cash Flow
30
Negative
Perimeter Medical Imaging AI faces challenges with negative operating and free cash flows, showing a decline in cash generation from operations. The free cash flow growth rate remains negative, indicating ongoing cash flow constraints. The ratios of operating and free cash flow to net income are both negative, reflecting difficulties in converting earnings into cash.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
625.73K403.53K132.77K11.34K0.000.00
Gross Profit
372.07K206.42K100.63K5.04K-47.57K-51.84K
EBIT
-18.88M-16.12M-16.05M-11.67M-13.02M
EBITDA
-15.46M-17.92M-11.72M-15.95M-6.11M-7.01M
Net Income Common Stockholders
-15.50M-18.94M-3.59M-16.76M-8.00M-10.50M
Balance SheetCash, Cash Equivalents and Short-Term Investments
1.21M18.43M28.44M5.14M11.70M1.21M
Total Assets
2.55M27.09M34.60M9.98M13.16M2.55M
Total Debt
14.21M192.89K325.68K441.17K400.81K14.21M
Net Debt
13.00M-18.18M-28.11M-4.28M-9.62M13.00M
Total Liabilities
19.03M7.10M8.49M2.56M2.40M19.03M
Stockholders Equity
-16.47M15.06M26.11M7.42M10.76M-16.47M
Cash FlowFree Cash Flow
-16.01M-15.17M-13.86M-16.03M-8.26M-5.83M
Operating Cash Flow
-15.64M-14.70M-11.87M-13.91M-8.26M-5.79M
Investing Cash Flow
48.01K206.01K-1.75M-1.45M7.24M-46.95K
Financing Cash Flow
7.07M234.47K40.28M10.06M9.84M5.20M

Perimeter Medical Imaging AI Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.26
Price Trends
50DMA
0.42
Negative
100DMA
0.48
Negative
200DMA
0.47
Negative
Market Momentum
MACD
-0.03
Positive
RSI
25.15
Positive
STOCH
1.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PINK, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.42, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 25.15 is Positive, neither overbought nor oversold. The STOCH value of 1.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PINK.

Perimeter Medical Imaging AI Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
C$105.13M-8.34%0.69%-95.27%
TSASG
55
Neutral
C$23.81M-23.87%18.97%17.57%
TSPRN
54
Neutral
C$219.39M-66.14%51.21%15.33%
53
Neutral
$5.20B3.32-45.04%2.84%16.81%-0.31%
50
Neutral
C$24.31M-163.62%113.85%11.38%
TSTLT
49
Neutral
C$52.03M-291.48%-8.63%7.04%
TSVPT
44
Neutral
C$17.95M207.08%280.56%-7.28%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:PINK
Perimeter Medical Imaging AI
0.26
-0.22
-45.83%
TSE:ASG
Aurora Spine
0.30
0.04
15.38%
TSE:QIPT
Quipt Home Medical
2.46
-2.11
-46.17%
TSE:PRN
Profound Medical
7.21
-3.09
-30.00%
TSE:TLT
Theralase Technologies
0.20
0.06
42.86%
TSE:VPT
VentriPoint Diagnostics
0.10
-0.14
-58.33%

Perimeter Medical Imaging AI Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
HonorHealth Adopts Perimeter’s Advanced Imaging Technology in Arizona
Positive
Apr 30, 2025

Perimeter Medical Imaging AI announced that HonorHealth is the first healthcare system in Arizona to implement its S-Series OCT technology, enhancing surgical decision-making with real-time, high-resolution imaging of tissue margins. This deployment marks a significant step in Perimeter’s nationwide expansion, increasing access to their technology in a major metropolitan area and reflecting the growing demand for improved surgical outcomes.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.

To see Spark’s full report on TSE:PINK stock, click here.

Business Operations and Strategy
Perimeter Medical Imaging AI to Present at 2025 Healthcare Investor Conference
Neutral
Apr 28, 2025

Perimeter Medical Imaging AI announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference, where it will present updates on its business. This participation underscores Perimeter’s ongoing efforts to enhance its industry presence and communicate its technological advancements, potentially impacting its market positioning and stakeholder engagement.

Spark’s Take on TSE:PINK Stock

According to Spark, TipRanks’ AI Analyst, TSE:PINK is a Neutral.

Perimeter Medical Imaging AI shows strong revenue growth and promising developments in product approval, positioning it for future expansion. However, persistent net losses, cash flow issues, and bearish technical trends pose significant challenges. The stock’s valuation is unattractive due to negative profitability. While the company is in a pivotal growth phase with potential regulatory milestones ahead, financial and operational hurdles must be overcome to enhance investor confidence.

To see Spark’s full report on TSE:PINK stock, click here.

Private Placements and FinancingBusiness Operations and Strategy
Perimeter Medical Imaging AI Announces Public Offering to Boost Commercialization Efforts
Positive
Mar 27, 2025

Perimeter Medical Imaging AI, Inc. announced a proposed public offering of units, consisting of common shares and purchase warrants, to raise funds for the commercialization of its technology, clinical evidence establishment, and product development. The offering, expected to close by the end of April 2025, will be conducted on a ‘best efforts’ basis with A.G.P. Canada Investments ULC as the agent, and aims to strengthen the company’s market position and operational capabilities.

Business Operations and StrategyFinancial Disclosures
Perimeter Medical Imaging AI Reports Strong 2024 Growth and Advances B-Series OCT Development
Positive
Mar 26, 2025

Perimeter Medical Imaging AI reported significant financial growth in 2024, with a 303% increase in Q4 revenues compared to the previous year, driven by the adoption of its S-Series OCT systems. The company is advancing its B-Series OCT system, having successfully completed a pivotal trial for breast-conserving surgeries and submitted a PMA application to the FDA. This progress positions Perimeter for further expansion and potential regulatory approval, which could enhance its market position and impact stakeholders positively.

Business Operations and StrategyFinancial Disclosures
Perimeter Medical Imaging AI to Announce 2024 Financial Results
Neutral
Mar 24, 2025

Perimeter Medical Imaging AI announced it will release its fourth quarter and full year 2024 financial results on March 26, 2025, followed by a conference call to discuss the outcomes and provide a corporate update. This announcement is significant as it may impact the company’s operations and industry positioning, especially considering its ongoing clinical trials and the potential market introduction of its next-generation imaging technology.

Product-Related AnnouncementsBusiness Operations and StrategyRegulatory Filings and Compliance
Perimeter Medical Imaging AI Submits FDA Application for Advanced Imaging System
Positive
Mar 17, 2025

Perimeter Medical Imaging AI has submitted a Premarket Approval application to the FDA for its B-Series OCT system with ImgAssist AI 2.0, aimed at improving outcomes in breast-conserving surgeries. The pivotal trial showed significant results in reducing residual cancer during surgery, suggesting potential widespread adoption among breast cancer surgeons if approved, marking a significant milestone for the company’s operations and industry positioning.

Product-Related AnnouncementsBusiness Operations and Strategy
Perimeter Medical’s Pivotal Trial Results to be Presented at ASBrS 2025
Positive
Mar 5, 2025

Perimeter Medical Imaging AI announced that its pivotal trial results for the B-Series OCT with ImgAssist AI 2.0 will be presented at the 2025 Annual Meeting of the American Society of Breast Surgeons. The trial showed a statistically significant reduction in residual cancer during surgery, supporting the company’s efforts to gain FDA approval for their next-generation imaging system. This development could enhance the adoption of their technology, providing surgeons with improved tools for breast cancer surgery.

Delistings and Listing ChangesBusiness Operations and Strategy
Perimeter Medical Imaging AI to Trade on OTCQX, Eyes U.S. Expansion
Positive
Feb 25, 2025

Perimeter Medical Imaging AI announced that its common shares will begin trading on the OTCQX Best Market, enhancing its visibility and efforts to expand its U.S. shareholder base. This move follows positive results from a pivotal study supporting the company’s FDA premarket approval submission for its B-Series OCT with ImgAssist AI, which demonstrated significant improvements in surgical outcomes, potentially reducing the need for reoperations.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.